EMAIL THIS PAGE TO A FRIEND

Journal of neuroinflammation

Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120-mediated brain inflammation.


PMID 24884548

Abstract

Neuroinflammation is a common immune response associated with brain human immunodeficiency virus-1 (HIV-1) infection. Identifying therapeutic compounds that exhibit better brain permeability and can target signaling pathways involved in inflammation may benefit treatment of HIV-associated neurological complications. The objective of this study was to implement an in vivo model of brain inflammation by intracerebroventricular administration of the HIV-1 viral coat protein gp120 in rats and to examine anti-inflammatory properties of HIV adjuvant therapies such as minocycline, chloroquine and simvastatin. Male Wistar rats were administered a single dose of gp120ADA (500 ng) daily for seven consecutive days, intracerebroventricularly, with or without prior intraperitoneal administration of minocycline, chloroquine or simvastatin. Maraviroc, a CCR5 antagonist, was administered intracerebroventricularly prior to gp120 administration for seven days as control. Real-time qPCR was used to assess gene expression of inflammatory markers in the frontal cortex, hippocampus and striatum. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) secretion in cerebrospinal fluid (CSF) was measured applying ELISA. Protein expression of mitogen-activated protein kinases (MAPKs) (extracellular signal-related kinase 1/2 (ERK1/2), c-Jun N-terminal kinases (JNKs) and P38 kinases (P38Ks)) was detected using immunoblot analysis. Student's t-test and ANOVA were applied to determine statistical significance. In gp120ADA-injected rats, mRNA transcripts of interleukin-1β (IL-1β) and inducible nitric oxide synthase (iNOS) were significantly elevated in the frontal cortex, striatum and hippocampus compared to saline or heat-inactivated gp120-injected controls. In CSF, a significant increase in TNF-α and IL-1β was detected. Maraviroc reduced upregulation of these markers suggesting that the interaction of R5-tropic gp120 to CCR5 chemokine receptor is critical for induction of an inflammatory response. Minocycline, chloroquine or simvastatin attenuated upregulation of IL-1β and iNOS transcripts in different brain regions. In CSF, minocycline suppressed TNF-α and IL-1β secretion, whereas chloroquine attenuated IL-1β secretion. In gp120-injected animals, activation of ERK1/2 and JNKs was observed in the hippocampus and ERK1/2 activation was significantly reduced by the anti-inflammatory agents. Our data demonstrate that anti-inflammatory compounds can completely or partially reverse gp120-associated brain inflammation through an interaction with MAPK signaling pathways and suggest their potential role in contributing towards the prevention and treatment of HIV-associated neurological complications.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2500010
Anti-ABCC1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA002380
Anti-ABCC1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1
SAB2100010
Anti-ABCC1 antibody produced in rabbit, affinity isolated antibody
SAB1406822
Anti-ABCG2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4300689
Anti-ABCG2 antibody produced in rabbit, affinity isolated antibody
SAB1406114
Anti-MDM4 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV06007
Anti-MDM4 antibody produced in rabbit, affinity isolated antibody
HPA018919 Anti-MDM4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4501852
Anti-MDM4 antibody produced in rabbit, affinity isolated antibody
SAB2103899
Anti-MDM4, (N-terminal) antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB1300711
Anti-MSH3 (center) antibody produced in rabbit, saturated ammonium sulfate (SAS) precipitated, buffered aqueous solution
SAB1406198
Anti-OCLN antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA005933
Anti-OCLN antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500301
Anti-OCLN antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2103797
Anti-OCLN, (N-terminal) antibody produced in rabbit, affinity isolated antibody
SAB1403023
Monoclonal Anti-ABCG2 antibody produced in mouse, clone 1G1, purified immunoglobulin, buffered aqueous solution
M0445
Monoclonal Anti-MDMX antibody produced in mouse, clone MDMX-82, purified from hybridoma cell culture
M9067
Monoclonal Anti-MRP1 antibody produced in mouse, ~2 mg/mL, clone QCRL-1, purified immunoglobulin, buffered aqueous solution
M9192 Monoclonal Anti-MRP1 antibody produced in mouse, ~2 mg/mL, clone QCRL-4, purified immunoglobulin, buffered aqueous solution
WH0004950M1
Monoclonal Anti-OCLN antibody produced in mouse, clone 1G7, purified immunoglobulin, buffered aqueous solution
AMAB90893
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1608, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90890
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1567, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90889
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1555, purified immunoglobulin, buffered aqueous glycerol solution
S6196
Simvastatin, ≥97% (HPLC), solid
C25H38O5
38956
Simvastatin, analytical standard
C25H38O5
1612700
Simvastatin, United States Pharmacopeia (USP) Reference Standard
C25H38O5
S0650000
Simvastatin, European Pharmacopoeia (EP) Reference Standard
C25H38O5
PHR1438
Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material
C25H38O5
Y0001066
Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard
C25H38O5